Notarte Kin Israel, Catahay Jesus Alfonso, Velasco Jacqueline Veronica, Pastrana Adriel, Ver Abbygail Therese, Pangilinan Flos Carmeli, Peligro Princess Juneire, Casimiro Michael, Guerrero Jonathan Jaime, Gellaco Ma Margarita Leticia, Lippi Giuseppe, Henry Brandon Michael, Fernández-de-Las-Peñas César
Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Department of Medicine, Saint Peter's University Hospital, New Brunswick, NJ, USA.
EClinicalMedicine. 2022 Aug 27;53:101624. doi: 10.1016/j.eclinm.2022.101624. eCollection 2022 Nov.
Although COVID-19 vaccination decreases the risk of severe illness, it is unclear whether vaccine administration may impact the prevalence of long-COVID. The aim of this systematic review is to investigate the association between COVID-19 vaccination and long-COVID symptomatology.
MEDLINE, CINAHL, PubMed, EMBASE, and Web of Science databases, as well as medRxiv and bioRxiv preprint servers were searched up to June 20, 2022. Peer-reviewed studies or preprints monitoring multiple symptoms appearing after acute SARS-CoV-2 infection either before or after COVID-19 vaccination collected by personal, telephone or electronic interviews were included. The methodological quality of the studies was assessed using the Newcastle-Ottawa Scale.
From 2584 studies identified, 11 peer-reviewed studies and six preprints were included. The methodological quality of 82% (=14/17) studies was high. Six studies (=17,256,654 individuals) investigated the impact of vaccines before acute SARS-CoV-2 infection (vaccine-infection-long-COVID design). Overall, vaccination was associated with reduced risks or odds of long-COVID, with preliminary evidence suggesting that two doses are more effective than one dose. Eleven studies (=36,736 COVID-19 survivors) investigated changes in long-COVID symptoms after vaccination (infection-long-COVID-vaccine design). Seven articles showed an improvement in long-COVID symptoms at least one dose post-vaccination, while four studies reported no change or worsening in long-COVID symptoms after vaccination.
Low level of evidence (grade III, case-controls, cohort studies) suggests that vaccination before SARS-CoV-2 infection could reduce the risk of subsequent long-COVID. The impact of vaccination in people with existing long-COVID symptoms is still controversial, with some data showing changes in symptoms and others did not. These assumptions are limited to those vaccines used in the studies.
The LONG-COVID-EXP-CM study supported by a grant of Comunidad de Madrid.
尽管新冠病毒疫苗接种可降低重症风险，但疫苗接种是否会影响长期新冠的患病率尚不清楚。本系统评价的目的是调查新冠病毒疫苗接种与长期新冠症状之间的关联。
检索了截至2022年6月20日的MEDLINE、CINAHL、PubMed、EMBASE和科学网数据库，以及medRxiv和bioRxiv预印本服务器。纳入了通过个人、电话或电子访谈收集的、对急性SARS-CoV-2感染后（无论在新冠病毒疫苗接种之前还是之后）出现的多种症状进行监测的同行评审研究或预印本。使用纽卡斯尔-渥太华量表评估研究的方法学质量。
从识别出的2584项研究中，纳入了11项同行评审研究和6篇预印本。82%（=14/17）的研究方法学质量较高。6项研究（=17256654人）调查了在急性SARS-CoV-2感染之前接种疫苗的影响（疫苗-感染-长期新冠设计）。总体而言，接种疫苗与长期新冠风险或几率降低相关，初步证据表明两剂比一剂更有效。11项研究（=36736名新冠病毒感染者幸存者）调查了接种疫苗后长期新冠症状的变化（感染-长期新冠-疫苗设计）。7篇文章显示接种至少一剂疫苗后长期新冠症状有所改善，而4项研究报告接种疫苗后长期新冠症状没有变化或恶化。
低证据水平（三级，病例对照、队列研究）表明，在SARS-CoV-2感染之前接种疫苗可降低后续长期新冠的风险。接种疫苗对已有长期新冠症状者的影响仍存在争议，一些数据显示症状有变化，而另一些则没有。这些假设仅限于研究中使用的那些疫苗。
长期新冠-EXP-CM研究由马德里自治区的一项拨款资助。
